United Therapeutics stock has delivered a 156.8% total return over the past five years, yet the broader valuation checks still point to shares looking cheap on several fronts. Recent news around ralinepag and organ manufacturing keeps expectations high, which makes the current pricing worth a closer look for anyone weighing upside against risk.

• A 156.8% five year return suggests United Therapeutics has already rewarded patient shareholders, so any further upside now needs support from fundamentals rather than momentum alone.
• Progress on ralinepag and the organ manufacturing pipeline can support longer term cash flow expectations, while the risk remains that new therapies or organ programs take longer or cost more to reach commercial scale than investors currently assume.
• United Therapeutics screens as undervalued on 5 out of 6 checks, and this high valuation score at 5 out of 6 suggests the broader metrics lean cheap rather than stretched.

The key question now is whether the current share price still offers an attractive entry point given that mix of strong past returns and a valuation profile that leans inexpensive.

Is United Therapeutics Still Cheap on Earnings?

The P/E ratio is a useful guide for United Therapeutics because earnings are a key driver for how investors compare mature biotech stocks. On this measure, United Therapeutics currently trades at about 17.3x earnings. That sits almost exactly in line with the Biotechs industry average of roughly 17.3x, yet it is below the peer group average of about 24.6x.

The fair P/E multiple for United Therapeutics is estimated at 28.0x based on its profile, which is well above where the stock trades today. Despite the recent focus on ralinepag and organ manufacturing progress, the current multiple still prices United Therapeutics at a discount to what this framework suggests. The gap between the current 17.3x and the 28.0x fair ratio indicates that investors are paying less for each dollar of earnings than this model implies they might need to for a stock with similar characteristics.

On the P/E test, United Therapeutics stock screens as undervalued relative to the earnings multiple suggested by this framework.

The United Therapeutics Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for United Therapeutics pick up where the P/E discussion leaves off. They spell out which future paths for United Therapeutics' growth, margins and earnings would need to play out for the stock to be worth materially more or less than today's price, and, rather than relying on a single multiple or model output, each one lays out its own assumptions so you can compare them with the actual results as they are reported.

Community views on United Therapeutics sit far apart, with one camp eyeing long runway potential and the other focused on concentration and patent risk.

Bull case: 31% undervalued

"United Therapeutics' unmatched leadership and real-world progress in groundbreaking technologies like xenotransplantation and organ manufacturing expose the company to entirely new, uncrowded multibillion-dollar markets..."

Bear case: roughly fairly valued

"This heavy reliance on a small number of key drugs, particularly Tyvaso and Remodulin, exposes the company to severe patent expiration and generic/biosimilar risk over the long term..."

Do you think there's more to the story for United Therapeutics? Head over to our Community to see what others are saying!

The Bottom Line

For investors looking at United Therapeutics today, the market-multiple work still points to a stock that screens as undervalued rather than fully priced. The broad valuation checks lean supportive; yet the debate turns on whether current earnings can be sustained and expanded as ralinepag and organ manufacturing progress, or whether concentration and patent risk keep a lid on the multiple. The crux from here is whether that apparent discount reflects an opportunity for patient holders or a market that is correctly pricing execution and portfolio risk.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.